Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by talisman47on Apr 05, 2021 1:25pm
253 Views
Post# 32937766

Facebook Live with Algernon.......my comments

Facebook Live with Algernon.......my commentsWas hoping to hear a discussion on the data ( good and bad ) and for Algernon to provide positive direction on where they are going from here...........came across as I don't think they know where they are going at  this point

Overall the facebook live session came across as lethargic and unenthusiatic on Chris Moreau's and Algernon's part. Nowhere near excited about ifenprodil as he once was. Not offering encouragement or potential positive outlook but more a session of  things don't seem to be working out like we thought, to do more costs money and do these results warrant spending more money , the feeling that FDA may not have intestested in them at this point and no indication or hint of any investors, big pharma interested in the Algernon story.

 I think they are realizing there are issues with ifenprodil being a repurposed drug ( trying to get big pharma to have any interest ) . Don't know if the data results are significant enough to interest them . Repurposing drugs have the positive benefits but there is the negative as well.

They said often before the data that regardless of vaccines coming out that there will always be a need for therapeutics ( now they say it may be harder to find patients for studies and with regards to EUA they suggest with millions of people being vaccinated now that the FDA  may not feel the urgency to look at Algernon and  ifenprodil unless it shows a major significance to help  and show strong enough  data results )

They don't seem to have the desire, the enegy or the money to want to take on a Phase 3........unless they can get funds from other sources ( grants, pharma investors, etc. ).

I try to still be a believer in the company ( have been an investor for over a year ) but without stock movement beyond the 25-35 cent range it gets more difficult. What do we expect to happen over the next 6 months......Chris, if you are reading this give us a plan !!

<< Previous
Bullboard Posts
Next >>